CONYGAR INVESTMENT COMPANY PLC (THE)

Regulatory Filings • May 18, 2023

National Storage Mechanism | Additional information

RNS Number : 8011Z

Conygar Investment Company PLC(The)

18 May 2023

18th May 2023

THE CONYGAR INVESTMENT COMPANY PLC

Planning approved for bioscience development

at The Island Quarter, Nottingham

The Conygar Investment Company PLC ("Conygar") is pleased to announce that Nottingham City Council has approved its detailed application for the next phase of The Island Quarter development in Nottingham. The application comprises a 23,123 sq.m. (249,000 sq.ft.) bioscience building, which includes both laboratory and office space. The permission is subject to the documenting of the section 106 agreement.

Robert Ware, Chief Executive of Conygar, commented:

"We are delighted that the next phase of development has been approved. Nottingham is already home to a large number of exciting businesses in the bioscience space and this scheme will be an excellent addition to the mixed-use development we are creating at The Island Quarter".

Enquiries:

The Conygar Investment Company PLC

Robert Ware: 020 7258 8670 

Liberum Capital Limited (Nominated Adviser and Broker)

Richard Lindley: 020 3100 2185

Temple Bar Advisory (Public Relations)

Alex Child-Villiers: 07795 425580

William Barker: 07827 960151

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKDLFFXELXBBV